On May 20, the Texas Pharmaceutical Initiative (TPI) Board convened to review and approve staff recommendations for the upcoming TPI Business Plan, due June 1. The Board also heard updates from the Texas Pharmaceutical Initiative Advisory Council (TPIAC) and representatives from covered agencies regarding activities related to pharmaceutical procurement and management. Finally, they discussed feedback collected by TPI staff from external stakeholders about the TPI Business Plan's implementation. 

Also in Texas, the Senate Health and Human Services Committee is scheduled to meet on May 27 to hear invited testimony on several interim charges related to rising healthcare insurance costs. The Committee will examine provider models for health care services, including, but not limited to, PBMs and health care facility fees, to determine whether these business practices are contributing to increased health care costs and insurance premiums. The Committee aims to identify strategies to lower health care costs and increase market flexibility, considering additional offerings such as Health Savings Accounts and new flexible plans. 

Also in Texas, the House Select Committee conducted two days of hearings, featuring invited testimony, to evaluate the key drivers of health care costs. These included statutory, regulatory and administrative burdens, as well as the effects of fraud, waste and abuse. The Committee also examined how insurance design, cost sharing, market structure and payment policies affect consumers and employers, with particular attention to how consolidation influences patient choice, market competition and the pricing and value of health care services. 

For more information, contact NACDS’ Mary Staples at 817-442-1155.